Qiagen Dirección

Dirección controles de criterios 4/4

El CEO de Qiagen's es Thierry Bernard , nombrado en Oct 2019, tiene una permanencia de 4.5 años. compensación anual total es $1.99M, compuesta por 49.1% salario y 50.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de €9.07M. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 9.8 años, respectivamente.

Información clave

Thierry Bernard

Chief Executive Officer (CEO)

US$2.0m

Compensación total

Porcentaje del salario del CEO	49.1%
Permanencia del CEO	4.6yrs
Participación del CEO	0.1%
Permanencia media de la dirección	6.3yrs
Promedio de permanencia en la Junta Directiva	9.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thierry Bernard en comparación con los beneficios de Qiagen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$337m
Dec 31 2023	US$2m	US$979k	US$341m
Sep 30 2023	n/a	n/a	US$485m
Jun 30 2023	n/a	n/a	US$490m
Mar 31 2023	n/a	n/a	US$353m
Dec 31 2022	US$10m	US$950k	US$423m
Sep 30 2022	n/a	n/a	US$488m
Jun 30 2022	n/a	n/a	US$539m
Mar 31 2022	n/a	n/a	US$563m
Dec 31 2021	US$2m	US$900k	US$513m
Sep 30 2021	n/a	n/a	US$311m
Jun 30 2021	n/a	n/a	US$480m
Mar 31 2021	n/a	n/a	US$449m
Dec 31 2020	US$2m	US$900k	US$359m
Sep 30 2020	n/a	n/a	US$191m
Jun 30 2020	n/a	n/a	US$14m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$1m	US$650k	-US$41m

Compensación vs. Mercado: La compensación total de Thierry($USD1.99M) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD3.35M).

Compensación vs. Ingresos: La compensación de Thierry ha sido consistente con los resultados de la empresa en el último año.

CEO

Thierry Bernard (58 yo)

4.6yrs

Permanencia

US$1,991,874

Compensación

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board since 2021 and had been its Interim Chief Executive Officer since Octo...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thierry Bernard	CEO, MD & Member of Management Board	4.6yrs	US$1.99m	0.11% $ 9.5m
Roland Sackers	CFO, MD & Member of Management Board	20.3yrs	US$1.07m	0.16% $ 14.2m
Antonio Santos	Senior VP & Head of Global Operations	2.1yrs	sin datos	sin datos
John Gilardi	Vice President of Corporate Communications & Investor Relations	13.6yrs	sin datos	sin datos
Stephany Foster	Senior VP & Head of Human Resources	4.6yrs	sin datos	sin datos
Thomas Schweins	Senior Vice President of Life Science Business Area	6.3yrs	sin datos	sin datos
Thomas Theuringer	Senior Director & Head of External Communications	no data	sin datos	sin datos
Jean-Pascal Viola	Senior VP & Head of Molecular Diagnostics Business Area	9yrs	sin datos	sin datos
Jonathan Sheldon	Senior Vice President of Qiagen Digital Insights Business Area	6.3yrs	sin datos	sin datos

6.3yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de QIA es experimentado (6.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Metin Colpan	Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board	20.3yrs	US$86.50k	0.19% $ 16.8m
Elizabeth Tallett	Independent Member of the Supervisory Board	12.9yrs	US$101.50k	0.022% $ 2.0m
Eva Pisa	Independent Member of the Supervisory Board	1.9yrs	US$68.50k	sin datos
Lawrence Rosen	Independent Chairman of Supervisory Board	10.9yrs	US$188.50k	0.0067% $ 602.7k
Toralf Haag	Independent Member of the Supervisory Board	3.3yrs	US$82.50k	0.0012% $ 105.8k
Elaine Mardis	Independent Member of the Supervisory Board	9.9yrs	US$79.50k	0.0018% $ 165.0k
Rick Bright	Member of Scientific Advisory Board	no data	sin datos	sin datos
Peter Kaspar	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Ross Levine	Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board	8.3yrs	US$68.50k	0.0075% $ 676.2k
Patrice Nordmann	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Neville Sanjana	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Sarah Polonius-Teichmann	Member of the Scientific Advisory Board	no data	sin datos	sin datos

9.9yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de QIA se considera experimentada (9.8 años de antigüedad promedio).

Qiagen Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Qiagen N.V., Annual General Meeting, Jun 21, 2024

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Board Member recently sold €204k worth of stock

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold €1.4m worth of stock

Qiagen N.V., Annual General Meeting, Jun 23, 2022

Recent updates

Qiagen N.V., Annual General Meeting, Jun 21, 2024

QIAGEN Announces the Availability of QCI Secondary Analysis

Qiagen N.V. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.39 in 1Q 2023)

QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use

Qiagen N.V. to Report Q1, 2024 Results on Apr 29, 2024

Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024

Full year 2023 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Qiagen N.V. Provides Earnings Guidance for Year 2024

Qiagen N.V. to Report Q4, 2023 Results on Feb 06, 2024

Qiagen N.V. Receives FDA Clearance of NeuMoDx CT/NG Assay for Use on Both Neumodx 96 and 288 Molecular Systems

QIAGEN N.V Launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for Improved Sample Processing and RNAisolation

QIAGEN Launches New QIAcuity Digital PCR Kits and Updated Software to Expand Use by Biopharma and Food Safety Customers

Qiagen Launches Complete Sample to Insight Workflow for Microbiome Research

Qiagen N.V. Reaffirms Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings released: EPS: US$0.34 (vs US$0.36 in 3Q 2022)

Qiagen N.V. to Report Q3, 2023 Results on Oct 30, 2023

QIAGEN Launches QuantiFERON-EBV RUO Assay, Facilitating Research of Cell-Mediated Immune Response to Epstein-Barr Virus

QIAGEN Extends AI Capabilities of its NGS interpretation Software QCI Interpret to Enable Clinical Exome Completeness

QIAGEN Enhances QIAwave Portfolio with New Nucleic Acid Extraction Kits

CFO, MD & Member of Management Board recently sold €1.2m worth of stock

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.42 in 2Q 2022)

Qiagen N.V. Revises Earnings Guidance for the Full Year 2023

Qiagen N.V. to Report Q2, 2023 Results on Aug 08, 2023

Now 21% undervalued after recent price drop

QIAGEN’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-Analysis of Tuberculosis Screening

Qiagen N.V. Provides Earnings Guidance for the Year 2023

Qiagen N.V. Reaffirms Its Full-Year 2023 Outlook

Full year 2022 earnings: EPS misses analyst expectations

Board Member recently sold €204k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$1.84 (vs US$2.36 in FY 2021)

Qiagen N.V. Provides Sales Guidance for the Full Year 2023

Qiagen Reportedly Weighs Sale of Minority Stake in its Bioinformatics Division

Qiagen N.V. to Report Q4, 2022 Results on Feb 07, 2023

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. from Telegraph Hill Partners and 1315 Capital, LLC for approximately $150 million.

Qiagen N.V. (NYSE:QGEN) acquired Verogen, Inc. for $150 million.

Now 20% undervalued

Now 21% undervalued

QIAGEN Receives U.S. Food and Drug Administration Approval for Companion Diagnostic to Mirati Therapeutics' Krazati in Non-Small Cell Lung Cancer

Qiagen N.V. Launches Monkeypox Test for NeuMoDx Platform to Fight Global Outbreak by Boosting Research and Surveillance

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Qiagen N.V. Revises Earnings Guidance for the Year 2022

Qiagen N.V. to Report Q3, 2022 Results on Nov 07, 2022

Now 21% undervalued after recent price drop

Qiagen N.V. Announces New Additions to its Comprehensive NeuMoDx Assay Menu for Organ Transplant-Associated Viruses

Price target increased to €50.58

QIAGEN N.V. Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

QIAGEN Adds New Biopharma Products to QIAcuity Digital PCR Portfolio and Launches Expert Custom Assay Design Service

Qiagen N.V. Raises Earnings Guidance for the Full Year 2022

Qiagen N.V. to Report Q2, 2022 Results on Jul 27, 2022

Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member

CFO, MD & Member of Management Board recently sold €1.4m worth of stock

QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels

Qiagen N.V., Annual General Meeting, Jun 23, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Qiagen N.V. Revises Net Sales Guidance for the Full Year 2022

Qiagen N.V. to Report Q1, 2022 Results on Apr 27, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

QIAGEN N.V. Provides Sales Guidance for the First Quarter and Full Year of 2022

Qiagen N.V. Announces New Generation of Quantiferon TB Test Gains Chinese Approval and Renewed WHO Recommendation

QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products

QIAGEN Expands QIAstat-Dx Syndromic Testing Menu and Announces Launch Plans for New QIAstat-Dx Rise Higher-Throughput Version

Qiagen N.V. Expands Quantiferon Portfolio in the Fight Against TB